GenAI and Pharmacovigilance: Perfect is the Enemy of Good
Disregarding novel developments on account of imperfection will postpone the advancement of scientific discovery.
Disregarding novel developments on account of imperfection will postpone the advancement of scientific discovery.
The Belgian drugmaker will use Accenture's INTIENT Pharmacovigilance to monitor the safety of its drugs, including those that are on the market and in clinical trials. Germany's Bayer inked a similar deal with Genpact last year.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.